BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time Bid/Ask 07:19:56 2024-07-17 am EDT | ||
| 1135.95 EUR / 1137.31 EUR | -2.89% |
|
| Current month | +1.67% | ||
| 1 month | +5.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 1,157 | -1.19% |
| 24-07-16 | 1,170 | -0.36% |
| 24-07-15 | 1,175 | -0.19% |
| 24-07-12 | 1,177 | +1.74% |
| 24-07-11 | 1,157 | -1.20% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 03:07 am EDT
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD52AQ |
| ISIN | DE000HD52AQ1 |
| Date issued | 2024-04-26 |
| Strike | 1,350 $ |
| Maturity | 2025-06-20 (339 Days) |
| Parity | 1 : 1 |
| Emission price | 822.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,187 € |
|---|---|
| Lowest since issue | 816.6 € |
| Spread | 1.36 € |
| Spread % | 0.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Certificates
- Certificat
